AIDS Related Lymphoma
5
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Treatment Research
7 treatments under study, led by Rituximab
Research Leaders
6 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 10 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
20.0%
1 terminated out of 5 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
A Registry Study on HIV-related Lymphoma
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
Research Network
Common Treatments
- Rituximab2
- Filgrastim1
- Retrospective Survival Analysis1
- Chop1
- Noninterventional Followup1
Active Sponsors
- National Cancer Institute (NCI)2
- AIDS Malignancy Consortium1
- Fondation Ophtalmologique Adolphe de Rothschild1
- Roche1
- French National Agency for Research on AIDS and Viral Hepatitis1
Top Investigators
Service de Medecine Interne Hopital A Beclere Clamart France
Inserm U 720
Rotkreuzklinikum München
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Related Conditions
- Anal Cancer1
- Hpvrelated Malignancy1
- Hiv Infections1
- Hiv Related Lymphoma1
- Aidsrelated Kaposi Sarcoma1